kpg-818
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2019 (NCT03949426)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CRL4(CRBN) E3 ubiquitin ligaseMODULATOR
CRL4(CRBN) E3 ubiquitin ligase modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04643067 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Kangpu Biopharmaceuticals, Ltd |
| NCT04283097 | Phase 1 | Mar 30, 2020 | Kangpu Biopharmaceuticals, Ltd |
| NCT03949426 | Phase 1 | May 15, 2019 | California Clinical Trials, Kangpu Biopharmaceuticals, Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kangpu Biopharmaceuticals, Ltd | For profit | 3 | 3 | 2 | 2019 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1